Status:
COMPLETED
A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy
Lead Sponsor:
University of Maryland, Baltimore
Conditions:
HIV Infections
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
We hypothesize that using a potent antiretroviral such as Enfuvirtide during the induction phase of HAART therapy will lead to faster clearance of virus and infected cells, and lower number of minorit...
Detailed Description
This is an 48 week Phase 4, open label, randomized, prospective, pilot proof of concept study to evaluate the use of Enfuvirtide in an induction/maintenance treatment model. Patients meeting inclusion...
Eligibility Criteria
Inclusion
- Age: 18 to 70 years of age.
- Sex: Male or Female.
- Documented HIV-1 seropositive by Western Blot, Elisa, or HIV-1 viral load.
- Naïve to HAART.
- Viral load \>100,000c/ml.
- CD4\<200c/ml.
- Volunteers must be willing and able to provide written informed consent to participate in the study.
- Available for at least 48 weeks of follow-up.
Exclusion
- Volunteers with an acute and clinically significant medical event as determined by the investigator to result in a life expectancy less then 12 months despite ART.
- Volunteers with current psychiatric illness, alcohol abuse or illicit drug use that in the opinion of the Principal Investigator may interfere with patient's ability to comply with protocol requirements.
- Renal insufficiency (Estimated Creatinine clearance of \<60ml/min.)
- Patients with malabsorption or severe chronic diarrhea for more than 30 days.
- Inability to consume adequate oral intake (defined as inability to eat at least 1 meal per day).
- Current treatment for malignancy other than basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
- Any other medical condition which, in the opinion of the investigator, might interfere with completion of the study or evaluation of the results.
- Pregnancy or breastfeeding
- In a female capable of child bearing, unwillingness to use effective barrier contraception or abstinence
- Patient who is currently receiving an experimental medication.
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2007
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT00344760
Start Date
January 1 2005
End Date
March 1 2007
Last Update
May 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Maryland, Institute of Human Virology
Baltimore, Maryland, United States, 21201